Arkema announces the proposed divestment of Febex, a company specialized in phosphorus-based chemistry, to Belgian group Prayon. Arkema thus continues its dynamic business portfolio management.
Febex is a global player in phosphorus derivatives (high purity phosphoric acid, sodium hypophosphite and derivatives), used primarily in electronics and in the pharmaceuticals industry. Part of the Performance Additives Business Line and with little integration within the Group’s other activities, Febex reported sales of around €30 million in 2021, employs 59 people, and operates 1 site in Switzerland.
By joining Prayon, an industrial group specialized in phosphorus-based chemistry, the Febex teams will benefit from the Belgian group’s growth ambitions in this area.
This project, which is expected to be finalized in 1st quarter 2023, is subject to information and prior consultation process with employee representative bodies in France and to approval by the relevant Swiss authorities.